CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 98 enrolled
Drug / intervention
Methoxy polyethylene glycol epoetin betadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01940484
NCT01940484N/ACompleted

An Observational, Non-Interventional Cohort Study to Observe the Efficacy and Use of MIRCERA in the Treatment of Chronic Renal Anaemia in Patients With Chronic Kidney Disease Stage V on Haemodialysis

Hoffmann-La Roche·observational·Posted Sep 12, 2013·Updated Jul 5, 2017

In Brief

An observational study evaluating Methoxy polyethylene glycol epoetin beta for Anemia. Completed, enrolled 98 participants across 10 sites.

Detailed Summary

This observational study will evaluate the efficacy and use of Methoxy polyethylene glycol-epoetin beta (Mircera) in participants with Stage V chronic kidney disease on hemodialysis receiving an erythropoietin prior to study entry. Attending physicians should have made the decision of placing the participant on methoxy polyethylene glycol epoetin beta in advance and not related to the study. The therapy will be administered by the attendant treating physician according to specifications in the package insert guidelines and to the routine of the site.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesSouth Africa
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 12, 2013
Enrollment StartAug 31, 2009
Primary CompletionJul 31, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.8 years ago

Interventions

Methoxy polyethylene glycol epoetin betadrug